ArticleScientific reports2026
Integrated virtual screening, ADMET profiling, and molecular dynamics simulations of novel natural HDAC6 inhibitors with the potential to ameliorate skeletal muscle degeneration.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Histone deacetylase 6 (HDAC6) helps maintain muscle health and regulates protein balance. In atrophic muscle, increased HDAC6 activity destabilizes microtubules and intensifies protein degradation. Therefore, selective HDAC6 inhibition is a promising approach to preserving muscle health. In this study, we conducted a comprehensive computational analysis, including virtual screening of 449,058 natural compounds from the SuperNatural 3.0 database, to identify novel natural HDAC6 inhibitors. The top candidates were filtered for drug-likeness and ADMET properties, then subjected to molecular docking and molecular dynamics simulations (MDS) to evaluate binding stability and energy profiles. The 20 best-scoring compounds (range of LibDock score: 120.54 to 167.81) were visually analyzed for their docking poses, and top-ranked compounds, SN0000021 and SN0000043, were selected for evaluation. Two natural compounds, SN0000021 and SN0000043, consistently showed strong predicted binding, favorable pharmacokinetic features, and stable interaction with the HDAC6 catalytic pocket throughout a 200-ns MDS. SN0000021 has moderate solubility, high Caco-2 permeability, and ~ 93% intestinal absorption, while SN0000043 shows slightly higher solubility, moderate permeability, and ~ 75% absorption. Both are AMES non-toxic and synthetically accessible. Free-energy calculations further confirmed their binding potential. These results indicate that SN0000021 and SN0000043 are plausible natural scaffolds for the development of selective HDAC6 inhibitors. Experimental validation in HDAC6 enzyme assays and SM models is required to confirm their anti-atrophic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.